avacopan: Clinical Trials

8 trials of avacopan, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 recruiting, 1 terminated. 8 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 28Completed 5, Recruiting 2, Terminated 1
Phase 31Recruiting 1

Follow avacopan: new trials by email Literature Review of avacopan trials Research Report on avacopan

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
Avacopan, Placebo - Granulomatosis With Polyangiitis, Wegener's
Phase 2 / Phase 3RecruitingRobert Spiera, MD302026-05-222026-09-02
Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
Avacopan, Prednisone, Methylprednisolone (drug) - IgA Nephropathy (IgAN)
Phase 2RecruitingMayo Clinic162025-06-092026-10-09
Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)
Avacopan, Placebo - Hidradenitis Suppurativa, Acne Inversa
Phase 2CompletedAmgen4352018-12-212025-03-17
Controlled Trial Evaluating Avacopan in C3 Glomerulopathy
Avacopan, Avacopan Matching Placebo - C3 Glomerulopathy (C3G)
Phase 2CompletedAmgen572017-09-292025-03-13
Complement Inhibition in aHUS Dialysis Patients
CCX168 - Atypical Hemolytic Uremic Syndrome
Phase 2TerminatedMario Negri Institute for Pharmacological Research62015-06-042017-11-14
Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade
CCX168 - Immunoglobulin A Nephropathy
Phase 2CompletedAmgen72015-03-272025-03-13
Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis
CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids, CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids, Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids - ANCA-associated Vasculitis
Phase 2CompletedAmgen422015-02-042025-03-13
A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis
Placebo, CCX168 - Vasculitis
Phase 2CompletedAmgen672011-09-012025-03-13

Conditions studied

Glomerulonephritis, IGA (2)  ·  Vasculitis (2)  ·  Abscess (1)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1)  ·  Atypical Hemolytic Uremic Syndrome (1)  ·  Glomerulonephritis, Membranoproliferative (1)  ·  Granulomatosis with Polyangiitis (1)  ·  Hidradenitis Suppurativa (1)  ·  Skin Diseases (1)

Sponsors

Amgen (5)  ·  Mario Negri Institute for Pharmacological Research (1)  ·  Mayo Clinic (1)  ·  Robert Spiera, MD (1)

Countries

United States (6)  ·  Belgium (2)  ·  Canada (2)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  Netherlands (2)  ·  Sweden (2)  ·  United Kingdom (2)  ·  Austria (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Hungary (1)  ·  Ireland (1)  ·  Poland (1)

Top investigators

Fernando Fervenza, MD (1)  ·  Giuseppe Remuzzi, MD (1)  ·  Lindsay Lally, MD (1)  ·  Nabeel Aslam, MD (1)  ·  Robert F Spiera, MD (1)

Results publications

PMID 24033923, PMID 33128347, PMID 34852172, PMID 39392695

NIH funding

2014 (2)